Pay in 4 interest-free payments of $6.32 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
The kicker
Patients are now more informed than ever regarding their health choices and are increasingly seeking out intravenous treatments for rapid health boosts and detoxification support
Understanding your personal timeline helps set realistic expectations and stay motivated during treatment
Most new patients will be seen within 1 week
Conclusions This analysis demonstrates that semaglutide 2.4 mg represents a cost-effective intervention for obese patients with MASH (F3) without diabetes within the Italian healthcare setting, generating substantial health gains and remaining below the commonly accepted willingness-to-pay threshold, reporting an ICER equal to 22,691 per QALY gained for the basecase scenario
US$ 20.13
US$ 22.03
US$ 27.66
US$ 22.70
US$ 27.80
